Sage Journals: Discover world-class research

Abstract

Background:

Natalizumab (NTZ) is a monoclonal antibody with an immunosuppressive effect that reduces the inflammation of the central nervous system, and it has been used for the treatment of relapsing-remitting multiple sclerosis (RRMS). In patients with low cellular immune response, systemic mycosis arising from endemic areas may occur.

Results and Conclusion:

In this article, we will describe a case of paracoccidioidomycosis as a complication to treatment with NTZ in an RRMS patient.

Keywords

Multiple sclerosis natalizumab paracoccidioidomycosis mycosis

Get full access to this article

View all access options for this article.

References

Rudick

Sandrock

. Natalizumab: Alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev Neurother 2004; 4: 571–580.

Nali

Moraes

Fink

et al . Natalizumab treatment for multiple sclerosis: Updates and considerations for safer treatment in JCV positive patients. Arq Neuropsiquiatr 2014; 72(12): 960–965.

Shikanai-Yasuda

Telles Filho Fde

Mendes

et al . Guidelines in paracoccidioidomycosis. Rev Soc Bras Med Trop 2006; 39(3): 297–310.

Multiple Sclerosis Therapy Consensus Group (MSTCG), Wiendl

Toyka

et al . Basic and escalating immunomodulatory treatments in multiple sclerosis: Current therapeutic recommendations. J Neurol 2008; 255: 1449–1463.

Steinman

. Blocking adhesion molecules as therapy for multiple sclerosis: Natalizumab. Nat Rev Drug Discov 2005; 4: 510–518.

Pulmonary paracoccidioidomycosis associated with the use of natalizumab in multiple sclerosis